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856Effects of Mismatching for Minor Histocompatibility
Antigens on Clinical Outcomes in HLA-Matched,
Unrelated Hematopoietic Stem Cell Transplants
Stephen Spellman,1 Melissa B. Warden,2 Michael Haagenson,3 Bradley C. Pietz,2
Els Goulmy,4 Edus H. Warren,5 Tao Wang,6 Thomas M. Ellis2Several studies in HLA-matched sibling hematopoietic stem cell transplantation (HSCT) have reported an as-
sociation between mismatches in minor histocompatibility antigens (mHAg) and outcomes. We assessed
whether single and multiple minor mHAg mismatches are associated with outcomes in 730 unrelated donor,
HLA-A, B, C, DRB1, and DQB1 allele-matched hematopoietic stem cell transplants (HSCT) facilitated by the
National MarrowDonor Program (NMDP) between 1996 and 2003. Patients had acute and chronic leukemia
or myelodysplastic syndrome (MDS), received myeloablative conditioning regimens and calcineurin inhibitor-
based graft-versus-host-disease (GVHD) prophylaxis, and most received bone marrow (BM; 85%). Donor
and recipient DNA samples were genotyped for mHAg including: HA-1, HA-2, HA-3, HA-8, HB-1 and
CD31125/563. Primary outcomes included grades III-IV acute GVHD (aGVHD) and survival; secondary out-
comes included chronic GVHD (cGVHD), engraftment, and relapse. Single disparities at HA-1, HA-2, HA-
3, HA-8, and HB-1 were not significantly associated with any of the outcomes analyzed. In HLA-A2-positive
individuals, single CD31563 or multiple mHAgmismatches in the HVG vector were associated with lower risk
of grades III-IV aGVHD. Based on these data, we conclude that mHAg incompatibility at HA-1, HA-2, HA-3,
HA-8, HB-1, and CD31 has no detectable effect on the outcome of HLA matched unrelated donor HSCT.
Biol Blood Marrow Transplant 15: 856-863 (2009)  2009 American Society for Blood and Marrow TransplantationKEYWORDS: Minor histocompatibility antigens, Graft-versus-host disease antigens, Unrelated donor trans-
plantation, Marrow and stem cell transplantationINTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
is the treatment of choice for a number of otherwise
untreatable malignancies and hematologic disorders.
Despite efforts to closely match recipients and donors,
HSCT is limited by high rates of complications, in-
cluding graft-versus-host disease (GVHD), poor en-
graftment, and disease recurrence [1]. HLA matching1National Marrow Donor Program, Minneapolis, Minne-
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6/j.bbmt.2009.03.018reduces, but does not prevent, the development of
GVHD. Rates of severe acute GVHD (aGVHD)
approach 28% in HLA identical unrelated donor
transplantation and 30% in HLA-matched sibling
transplants [2–6].
Disparities in minor histocompatibility antigens
(mHAg) underlie the development of GVHD in
HLA identical transplants [7–9]. mHAg are peptides
derived from allelic variants of normal cellular pro-
teins, which, when presented by self-class I or II major
histocompatibility complex (MHC) antigens, induce
cellular immune responses in HLA-matched individ-
uals lacking the same allelic variant. These protein/
peptide variants most often arise because of single
nucleotide polymorphisms (SNPs) or deletions. Cyto-
toxic T lymphocytes directed against mHAg have been
isolated from recipients of HLA-matched transplants
with aGVHD, and cytotoxic T cell clones from such
patients have been used to identify and characterize
mHAg [10–16]. Although some mHAg are ubiqui-
tously expressed (HA-3, HA-8), most have more
restricted tissue expression, including HA-1, HA-2
(hematopoietic tissue), CD31 (platelets, endothelial
cells), and HB-1 (B lymphoblastoid cells) [17,18].
Table 1. Patient Demographics
N Eval N (%)
Number of recipient/donor pairs 730
Number of centers 83
Age, median (range), years 729 37 (<1-65)
Age at transplant 729
<10 years 50 ( 7)
11-20 years 67 ( 9)
21-30 years 123 (17)
31-40 years 175 (24)
41-50 years 193 (26)
Over 50 years 121 (17)
Karnofsky prior to transplant $90 686 506 (74)
Disease at transplant 730
AML 210 (29)
ALL 150 (21)
CML 242 (33)
MDS 128 (17)
Disease status at transplant 730
Early 329 (45)
Intermediate 231 (32)
Advanced 119 (16)
Other 51 ( 7)
Graft type 730
Bone marrow 623 (85)
PBSC 107 (15)
Donor/recipient sex match 730
Male/male 288 (40)
Male/female 190 (26)
Female/male 110 (15)
Female/female 142 (19)
Donor/recipient CMV match 730
Negative/negative 275 (38)
Negative/positive 194 (26)
Positive/negative 101 (14)
Positive/positive 140 (19)
Biol Blood Marrow Transplant 15:856-863, 2009 857Minor Antigen Mismatching in Unrelated DonorsThere likely exist thousands of protein variants with
the potential of functioning as mHAg, although only
about 2 dozen human mHAg have been identified [19].
The role for mHAg disparities in HSCT outcomes
has been supported by studies showing higher rates of
aGVHD and lower survival in HLA-identical sibling
transplant recipients who are mHAg disparate
[20–24]. Mismatches in individual mHAg, including
HA-1, HA-2, HA-8, and CD31, have been associated
with increased rates of GVHD, and lower rates of leu-
kemia recurrence observed in pairs who are disparate
at HA-1 or HA-2 suggest a role for such disparities
in graft-versus-leukemia (GVL) effects [20,21], al-
though this is disputed by other studies [25]. Addition-
ally, disparities in HA-8 and CD31 were associated
with decreased patient survival [20–24]. Mismatching
for HA-1 in HLA-identical, HLA-A2 sibling pairs,
was previously reported to be associated with higher
rates of aGVHD and a possible GVL effect [20,21].
However, investigation of the role of mHAg in trans-
plant outcomes has been limited, because of the re-
quirement to restrict studies to recipient/donor pairs
expressing specific HLA types, as well as by the low
frequencies of some mHAg alleles [25].
In this study, we investigated the effect of single
and multiple disparities in autosomal mHAg on
HSCT outcomes in 730 recipients of HLA-matched
unrelated donor HSCTs.Unknown 20 ( 3)
Donor age, median (range), years 730 35 (19-60)
Year of transplant
1996-1999 352 (48)
2000-2003 378 (52)
Median follow-up of survivors, months 60 (10-107)
PBSC indicates peripheral blood stem cells; CMV, cytomegalovirus;
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myelogenous leukemia; MDS, myelodysplastic syndromes.MATERIALS AND METHODS
Patient Population
Recipient/donor pairs from 730 unrelated HLA-A,
B, C, DRB1, and DQB1 allele-matched transplants fa-
cilitated by the National Marrow Donor Program
(NMDP) were studied. HLA typing was confirmed
through the NMDP’s ongoing retrospective high-
resolution typing project as previously described
[26]. The majority (86%) of the pairs were mismatched
at HLA-DP. Transplants were performed between
1996 and 2003, and patient disease characteristics are
summarized in Table 1. Eligible diagnoses included
acute lymphoblastic leukemia (ALL), acute myeloge-
nous leukemia (AML), chronic myelogenous leukemia
(CML), and myelodysplastic syndrome (MDS). Early-
stage disease was defined as AML and ALL in first
complete remission (CR1), CML in first chronic phase
(CP1), and MDS subtype refractory anemia. Interme-
diate stage disease was AML or ALL in second or sub-
sequent complete remission or in first relapse, and
CML in accelerated phase or second chronic phase
(CR2). Advanced phase disease was AML in second
or higher relapse or primary induction failure, CML
in blast phase, MDS subtypes refractory anemia with
excess blasts (RAEB) or in transformation, or MDS
not otherwise classified. All patients received myeloa-blative conditioning regimens defined as ‘‘traditional,’’
if single-dose total body irradiation (TBI) was .500
cGy, or . 800 cGy total in fractionated doses (with
or without cyclophosphamide [Cy]), or Cy with at least
9.5 mg/kg busulfan (Bu), or ‘‘nontraditional,’’ if condi-
tioning included at least 9.5 mg/kg Bu without Cy or
melphalan (Mel) with a dose greater than 150 mg/m2.
All surviving recipients included in this analysis were
retrospectively contacted and provided informed
consent for participation in the NMDP research
program. Informed consent was waived by the NMDP
institutional review board for all deceased recipients.
Approximately 4% of surviving patients would not
provide consent for research. To adjust for the potential
bias introduced by exclusion of nonconsenting surviving
patients, a modeling process randomly excluded appro-
priately the same percentage of deceased patients using
a biased coin randomization with exclusion probabilities
based on characteristics associated with not providing
consent for use of the data in survivors [6].
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Recipient/donor samples were obtained from the
NMDP Research Repository and included whole fro-
zen blood, buffy coats, peripheral blood mononuclear
cells (PBMCs), and DNA. Genotyping was performed
on a panel of mHAg using a Luminex based, multiplex
assay developed at the BloodCenter of Wisconsin, as
described previously [25]. The mHAg panel and
HLA restriction are summarized in Table 2. The
mHAg panel was constructed to include well-charac-
terized polymorphisms that have been demonstrated
in previous studies to affect outcomes in HLA-
matched sibling transplants. Briefly, the assay is per-
formed in multiple steps using EraGen Biosciences’s
(Madison, WI) MultiCode Plx technology [27,28].
The assay is initiated with a multiplex polymerase
chain reaction (PCR) amplification of target mHAg
loci followed by allele-specific primer extension reac-
tions that specifically incorporate a 30 -biotin mole-
cule. Hybridization of biotinylated extension
products to EraCode-tagged Luminex xMAP beads
is performed at room temperature and is then fluores-
cently labeled with streptavidin phycoerythrin
(SA-PE) conjugate. Finally, the labeled xMAP beads
are detected on a Luminex 100 instrument (Austin,
TX). Genotypes are assigned based on the ratios of
the relative fluorescein signals detected on paired
Luminex beads that distinguish alternate forms of
each mHAg allele. Primers used for mHAg locus-
specific amplification and allele-specific extension re-
actions were synthesized by EraGen Biosciences.
mHAg mismatches and mismatch vectors, GVH or
host versus graft (HVG), or both, were assigned based on
known mHAg genotypes (Table 2). With the exception
of CD31 and HB-1, whose alternate alleles both encode
mHAg, the antigenic peptide that comprises the mHAg
for HA-1, -2, -3, and -8, is encoded by only 1 of the 2
alleles [11,14,29–31]. For these latter mHAg, mis-
matches occurred in either the GVH or HVG direction,
not both. Both CD31125 and CD31563 isoforms were
genotyped; however, only differences at CD31563 wereTable 2. mHAg Panel
mHAg HLA Restriction
Effect of Disparity
in HLA Matched
Sibling HSCT References
HA-1 HLA-A2 Increased acute GVHD/GVL effect [20-22]
HA-2 HLA-A2 Increased acute GVHD/GVL effect [20,22]
HA-3 HLA-A1 No effect on GVHD [20]
HA-8 HLA-A2 Increased acute GVHD, decreased
survival
[34]
HB-1 HLA-B44 Unknown
CD31 unknown Increased acute GVHD, decreased
survival
[23,24]
GVHD inidcates graft-versus-host disease; GVL, graft-versus-leukemia;
HSCT, hematopoietic stem cell transplantation; mHAg, minor histocom-
patibility antigens.analyzed because of the strong linkage between
CD31125 and CD31563 polymorphisms.
Definitions of Outcomes
The primary outcomes of the analysis were overall
survival (OS), defined as time from graft infusion (day
0) to death from any cause, and grades III-IV aGVHD,
defined by the Glucksberg scale [32]. A number of
secondary endpoints were also analyzed. Failure to
engraft (primary graft failure) was defined as failure
to achieve an absolute neutrophil count (ANC) greater
than 500  106/L by day 28, which was maintained
for 3 consecutive measurements. Extensive cGVHD
(cGVHD) was defined according to the Seattle criteria
[33]. Clinical relapse of the primary disease was de-
fined by the Center for International Blood and Mar-
row Transplant Research (CIBMTR) criteria [26].
Treatment-related mortality (TRM) is death in con-
tinuous complete remission of the primary disease.
Disease-free survival (DFS) is survival in continuous
complete remission of the primary disease.
Statistical Analysis
For evaluation of mHAg matching, the cases were
selected based on the previously described HLA re-
strictions for mHAg presentation. The sample size
for each HLA restriction group, that is, HLA-A1, A2
and B44, is noted in Table 3. For discrete factors,
the number of cases and their respective percentages
were calculated. Chi-square tests were used to com-
pare discrete factors between mHAg matched versus
1 mismatch versus$2 mismatches groups. For contin-
uous factors, the median and ranges were calculated.
The Kruskal-Wallis test was used to compare the con-
tinuous factors between mHAg matched versus 1 mis-
match versus$2 mismatches groups. Probabilities for
OS were calculated using the Kaplan-Meier estimator
with variance estimated by Greenwood’s formula.
Comparison of survival curves was done using the
Log-Rank test. Values for other outcomes were
calculated according to cumulative incidence using
a Taylor series linear approximation to estimate the
variance.
Multivariate analyses were performed using the
proportional hazards model to compare the mHAg
matched versus 1 mismatch versus $2 mismatches
groups with adjustment for statistically significant
covariates. Because of multiple comparisons, the sig-
nificance threshold was set at P\ .01. Potential cova-
riates include patient age, sex, race, Karnofsky
performance status, time from diagnosis to HCT, do-
nor type, donor-recipient sex match, cytomegalovirus
(CMV) serologic status, type of conditioning regimen,
graft source, year of transplantation, and GVHD pro-
phylaxis regimen. Models were fit to determine which
risk factors were related to a given outcome. All
Table 3. Power to Detect a Difference in Overall Survival for Individual and Combined mHAg
mHAg HLA Restriction
mHAgs Mismatched
in GVH Vector N (Mismatched:Matched)
Power to Detect 5% Increase
in Overall Survival
Power to Detect 10% Increase
in Overall Survival
HLA-A*01 (N 5 327) HA-3 and CD31 18:173 7% 13%
HA-3 or CD31 136:173 15% 43%
CD31 86:123 11% 31%
HA-3 42:249 9% 22%
HLA-A*02 (N 5 430) HA-1,HA-2, HA-8 and/or CD31 90:161 12% 34%
HA-1,HA-2, HA-8 or CD31 179:161 16% 48%
CD31 96:164 12% 35%
HA-1 90:228 13% 37%
HA-2 19:397 7% 13%
HA-8 95:269 14% 39%
HLA-B*44 (N 5 257) HB-1 and CD31 26:120 7% 15%
HB-1 or CD31 111:120 12% 34%
CD31 52:106 9% 22%
HB-1 61:129 10% 25%
No known
restriction (N 5 730)
CD31 174:280 19% 56%
mHAg indictes minor histocompatibility antigens; GVH, graft-versus-host.
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tional hazards assumption. Factors violating the pro-
portional hazards assumption were adjusted for by
stratification. Stepwise model building approach was
used in developing models for the primary and second-
ary outcomes.
Cox regression models were used to evaluate the as-
sociation between transplant outcomes versus match/
mismatch at any single mHAg, mismatches at 2 mHAg
versus 1 or no mismatches, and the directionality of the
mismatch (GVH, HVG). Table 3 summarizes the sam-
ple size used for each analysis, and the power to detect
both a 5% and 10% difference in survival.RESULTS
Single mHAg mismatches
A single mismatch in either direction (GVH or
HVG) for HA-1, HA-2, HA-3, HA-8, and HB-1,Table 4. Multivariate Results: Single mHAg Mismatches
HLA Restriction/mHAg/Vector
Survival Acute
RR 95%CI P Value RR 9
A1 CD31 GVH MM versus Matched 0.95 0.65–1.40 .81 0.59 0.3
HVG MM versus Matched 0.89 0.60–1.32 .56 0.71 0.3
HA-3 GVH MM versus Matched 1.46 0.95–2.25 .08 0.79 0.4
HVG MM versus Matched 1.53 0.98–2.40 .06 1.07 0.5
A2 CD31 GVH MM versus Matched 0.92 0.65–1.29 .63 0.88 0.5
HVG MM versus Matched 0.65 0.46–0.92 .02 0.41 0.2
HA-1 GVH MM versus Matched 1.27 0.92–1.74 .14 1.05 0.6
HVG MM versus Matched 1.03 0.76–1.41 .85 0.78 0.5
HA-2 GVH MM versus Matched 1.14 0.63–2.04 .67 1.18 0.5
HVG MM versus Matched 1.09 0.52–2.28 .81 0.45 0.1
HA-8 GVH MM versus Matched 1.19 0.86–1.63 .30 0.93 0.6
HVG MM versus Matched 1.18 0.82–1.71 .37 0.70 0.4
B44 CD31 GVH MM versus Matched 0.87 0.55–1.36 .54 1.24 0.6
HVG MM versus Matched 1.02 0.66–1.57 .94 0.95 0.5
HB-1 GVH MM versus Matched 1.00 0.66–1.52 .99 1.35 0.7
HVG MM versus Matched 0.91 0.57–1.46 .70 0.96 0.5
GVH indicates graft-versus-host; HVG, host-versus-graft; GVHD, graft-versu
myeloma; TRM, treatment-related mortality.was not significantly associated with any outcome an-
alyzed at P\ .01. Table 4 summarizes the 95% confi-
dence intervals (CIs) for the effects of single mHAg
mismatches on survival, grades III-IV aGVHD,
TRM, and cGVHD. In no case was the relative risk
(RR) significantly different than 1, at P\ .01 for any
mHAg, regardless of the directionality of the mis-
match. Low statistical power because of small sample
size shows the limited power of the analysis (Table 3).
The only significant finding occurred in HLA-A2
positive pairs where there was a significantly reduced
risk of grades III-IV GVHD when pairs were mis-
matched for CD31563 in the HVG direction (RR 5
0.41; CI5 0.24-0.71; P5 .001). Note that a similar as-
sociation was not observed for HLA-A1 (RR 5 0.71;
CI 5 0.39-1.29; P 5 .26) or B44 positive pairs (RR
5 0.95; CI 5 0.53-1.71; P 5 .86) and comparison of
outcomes of all CD31563-mismatched recipient donor
pairs without regard to HLA type showed no signifi-
cant association with any outcome when comparedGVHD III-IV TRM cGVHD
5%CI P Value RR 95%CI P Value RR 95%CI P Value
3–1.06 .08 1.15 0.74–1.78 .53 0.89 0.57–1.38 .60
9–1.29 .26 0.94 0.58–1.52 .81 1.28 0.84–1.94 .25
0–1.58 .51 1.37 0.83–2.28 .22 1.22 0.72–2.08 .45
2–2.19 .86 1.33 0.77–2.31 .30 1.12 0.67–1.89 .67
7–1.36 .57 1.03 0.69–1.53 .89 0.87 0.59–1.28 .48
4–0.71 .001 0.65 0.42–0.99 .04 0.88 0.61–1.25 .47
7–1.63 .83 1.13 0.76–1.67 .55 0.89 0.61–1.29 .54
0–1.21 .27 1.09 0.76–1.57 .65 0.83 0.59–1.17 .28
5–2.57 .67 1.55 0.81–2.96 .18 1.26 0.65–2.45 .49
1–1.84 .27 1.16 0.50–2.68 .73 0.91 0.42–1.97 .81
0–1.43 .73 1.00 0.68–1.47 .99 0.96 0.68–1.36 .82
0–1.22 .21 1.04 0.67–1.61 .86 0.91 0.61–1.35 .63
7–2.28 .49 1.09 0.64–1.85 .45 0.79 0.50–1.27 .33
3–1.71 .86 0.80 0.46–1.42 .75 0.70 0.44–1.09 .11
6–2.40 .30 0.99 0.59–1.66 .96 0.77 0.49–1.22 .27
3–1.71 0.91 0.97 0.55–1.73 .92 0.90 0.56–1.42 .64
s-host disease; RR, relative risk, CI, confidence interval; MM, multiple
860 Biol Blood Marrow Transplant 15:856-863, 2009S. Spellman et al.to CD31 matched pairs (data not shown). Because pre-
vious studies indicated that donors who were heterozy-
gous for the CD31563 polymorphism were associated
with poorer survival posttransplant [24], we compared
outcomes from transplants with 361 donors who were
heterozygous for the CD31563 SNP with 368 donors
homozygous for this SNP. No association with
survival was observed (RR 5 0.92; 95% CI 5 0.75-
1.11). Likewise, no significant association was ob-
served between a specific recipient or donor CD31563
allele and any outcome analyzed (data not shown).
An analysis of the impact of HY antigen disparities,
a proved mHAg, was also conducted on the complete
dataset using sex match, that is, female donor into
male recipient, as a surrogate for HY disparity. No
effect of HY mismatching was observed for any
outcome in the analysis (data not shown).
Multiple mHAg Mismatches
The effect of multiple mHAg mismatches was de-
termined by comparing outcomes for recipient/donor
pairs based on the total number of mismatched mHAg
for each HLA restriction (Table 5). Specific compari-
sons were grouped according to HLA restriction and
included pairs mismatched at 2 mHAg versus 1 or no
mismatches in both GVH and HVG directions.
When the effects of multiple mHAg mismatches
were analyzed, a reduced risk of aGVHD was observed
among HLA-A2-positive pairs who were mismatched
for 2 or more mHAg for HA-1, HA-2, HA-8, and/or
CD31563 in the HVG direction (RR 5 0.41; CI 5
0.23-0.73; P5 .003) when compared to matched pairs,
perhaps reflecting the influence of CD31563 mismatch-
ing on this group. HLA-A2 positive pairs who were
mismatched for 2 or more mHAg (HA-1, HA-2,
HA-8, and/or CD31563) in the GVH direction
appeared to have lower survival (RR 5 1.54; CI 5Table 5. Multivariate Results: Multiple mHAg Mismatches
HLA Restriction/mHAg/Vector
Survival
RR 95% CI P Value R
A1 HA-3 or CD31 GVH MM versus Matched 0.85 0.61–1.17 .31 0
HA-3 and CD31 GVH MM versus Matched 2.01 1.14–3.55 .02 0
HA-3 or CD31 HVG MM versus Matched 0.93 0.67–1.27 .63 0
HA-3 and CD31 HVG MM versus Matched 1.76 0.97–3.19 .06 1
A2 HA-1, HA-2, HA-8 or CD31 GVH MM
versus Matched
1.15 0.86–1.53 .35 1
HA-1, HA-2, HA-8 and/or CD31 GVH MM
versus Matched
1.54 1.09–2.18 .01 1
HA-1, HA-2, HA-8 or CD31 HVG MM
versus Matched
0.85 0.64–1.13 .25 0
HA-1, HA-2, HA-8 and/or CD31 HVG MM
versus Matched
0.90 0.63–1.30 .58 0
B44 HB-1 or CD31 GVH MM versus Matched 1.19 0.83–1.70 .35 0
HB-1 and CD31 GVH MM versus Matched 0.82 0.44–1.55 .54 1
HB-1 or CD31 HVG MM versus Matched 0.95 0.66–1.35 .77 0
HB-1 and CD31 HVG MM versus Matched 1.28 0.68–2.41 .45 0
GVHD indicates graft-versus host diesase; RR, relative risk; CI, confidence int
host-versus-graft; MM, multiple myeloma.1.09-2.18; P 5 .01). Likewise, there was a suggestion
that HLA-A1-positive individuals mismatched for
both CD31 and HA-3 in the GVH direction had de-
creased survival and increased TRM compared to
matched pairs (OS: RR 5 2.01; 95% CI 5 1.14-3.55;
P 5 .02; and TRM: RR 5 2.28; 95% CI 5 1.17-
4.44; P 5 .02); however, neither result met the signif-
icance threshold of P\ .01 set for the study because of
multiple comparisons (Table 5). No other multiple
mHAg mismatches were associated with any of the
outcomes analyzed in any of the HLA-restriction
groups.DISCUSSION
This comprehensive analysis is the first to examine
the role of mHAg disparities in the outcome of HLA-
matched unrelated HSCT and failed to corroborate
results in HLA-identical sibling transplants where sin-
gle mHAg mismatches have been associated with sig-
nificantly increased rates of aGVHD (HA-1, HA-2,
HA-8, and CD31), decreased survival (HA-8, CD31),
and lower rates of disease recurrence (HA-1, HA-2)
[20–24,34–36]. The present study comprised the larg-
est number of HLA-matched recipient/donor pairs
evaluated to date. Nevertheless, small subgroup size
and the greater disparity in HLA and non-HLA-
associated polymorphic genes between unrelated do-
nor/recipient pairs may have limited the power of
our analysis [37]. Other limitations of the study include
a predominance of BM as a graft source and a low
number of patients under the age of 20 years, which
may restrict the relevance of these findings in PB and
pediatric transplants.
We did observe that single CD31563 mHAg mis-
matches in the HVG vector in HLA-A2-positive indi-
viduals were found to potentially reduce the risk ofAcute GVHD III-IV TRM Chronic GVHD
R 95% CI P Value RR 95% CI P Value RR 95%CI P Value
.78 0.49–1.23 .28 0.92 0.63–1.34 .68 1.01 0.71–1.42 .98
.76 0.27–2.16 .61 2.28 1.17–4.44 .02 0.69 0.25–1.91 .48
.95 0.59–1.53 .85 0.84 0.57–1.24 .39 1.31 0.93–1.84 .13
.50 0.58–3.83 .40 1.59 0.79–3.23 .20 1.09 0.47–2.54 .84
.16 0.77–1.74 .47 1.05 0.74–1.48 .81 1.25 0.91–1.71 .17
.22 0.76–1.95 .41 1.52 1.02–2.26 .04 0.87 0.59–1.29 .50
.69 0.48–1.00 .05 0.89 0.63–1.25 .50 1.09 0.80–1.48 .59
.41 0.23–0.73 .003 0.93 0.60–1.44 .76 0.72 0.47–1.10 .13
.90 0.54–1.50 .68 1.31 0.84–2.04 .24 0.60 0.41–0.89 .0114
.55 0.76–3.16 .23 1.08 0.52–2.22 .84 1.05 0.61–1.83 .85
.89 0.54–1.45 .63 0.81 0.53–1.26 .35 0.96 0.67–1.38 .84
.62 0.24–1.60 .33 1.11 0.51–2.39 .79 0.57 0.27–1.20 .14
erval, TRM, treatment-related mortality; GVH, graft-versus-host; HVG,
Biol Blood Marrow Transplant 15:856-863, 2009 861Minor Antigen Mismatching in Unrelated Donorsdeveloping grades III-IV aGVHD, although the bio-
logic mechanism remains unclear. Significant associa-
tions with outcomes were also observed for multiple
mismatches in HLA-A1-positive recipient donor pairs;
mismatching at HA-3 plus CD31 in the HVG direc-
tion was associated with increased survival and de-
creased TRM, and, in HLA-A2 pairs mismatched for
HA-1, HA-2, HA-8, or CD31in the HVG direction,
there was a significantly lower rate of aGVHD, but
may reflect the influence of CD31 mismatching. In
all cases, it is unclear whether the differences reflect
a true biologic impact of mismatching or a random ef-
fect.
In HLA-identical sibling transplants HA-3 dispar-
ity alone had no impact on GVHD, whereas multiple
studies indicated that CD31 nonidentity is a significant
risk factor for OS and aGVHD [24]. Any clinical risk of
HA-3 mismatching is minimized by the fact that a ma-
jority of Caucasians (77%) express the HA-3 mHAg,
making the likelihood of a mismatch low. It is notewor-
thy that, in contrast to the majority of the other mHAg
studied, HA-3 and CD31 are not restricted to hemato-
poietic cells, but have a wide range of cell and tissue ex-
pression. CD31 (PECAM-1) functions as a homotypic
adhesion molecule that is expressed on a variety of cells
and tissues, including endothelial cells, platelets, and
leukocytes. CD31 has never been directly demon-
strated to be immunogenic nor function as an mHAg,
as this latter property has been implied indirectly
through the demonstration that recipient/donor pairs
mismatched for CD31 allelic forms have higher risks
of GVHD [24]. Cavanagh et al. [24] showed that donor
heterozygosity for CD31563 alleles was associated with
decreased survival in matched sibling HSCT, a finding
that suggests that any effect of CD31 polymorphisms
on HSCT outcomes may instead reflect inherent func-
tional properties of CD31 isoforms and are not because
of mHAg effects. However, we failed to confirm this ef-
fect in unrelated donor HSCT and further failed to ob-
serve any significant association between the presence
of specific CD31 alleles in the recipient or donor and
any outcome (data not shown).
Although the present study comprised the largest
number of fully HLA-matched unrelated donor
HSCT cases evaluated to date, statistical power to de-
tect significant differences was low for many compari-
sons in part because of the relative infrequency of some
mHAg alleles, low likelihood of mismatches (e.g., HA-
2, HA-3) [25], and the study size limitations resulting
from mHAg HLA presentation restrictions. In addi-
tion to the mHAg panel, analysis of the mHAg effects
of HY disparity was also negative, potentially because
of low power, with only 15% of the population at risk.
Given these considerations, statistical power will re-
main a limitation to the characterization of mHAg dis-
parities on unrelated HSCT outcomes. However, it
should be noted that the original effects of HA-1 andHA-2 mismatching in HLA identical sibling HSCT
outcomes were detected with as few as 117 HLA-A2-
positive study subjects, in contrast to the present study,
which involved 430 HLA-A2-positive unrelated pairs
[20,22]. These findings suggest that additional HLA
disparities (HLA-DP) and other factors may mask
the impact of mHAg disparity in unrelated donor
HSCT.
The majority of the current study population
(86%) was mismatched at HLA-DP, which has been
recently associated with an increased risk of aGVHD
and lower relapse rates in unrelated donor HSCT
[37]. The high rate of HLA-DP mismatching in our
population may obsure any contributions of mHAg
mismatching to risk of aGVHD in unrelated donor
HSCT. By extension, the clinical impact of mHAg dis-
parities in unrelated HSCT may be rendered moot
given the likelihood that recipient/donor pairs who
are selected based on allele-level matching at HLA-
A, B, C, DRB1, and DQB1 are likely to be mismatched
at HLA-DP. Another hypothesis to explain our find-
ings is differences in patient immunosuppression and
management, as risk for HA-1 associated GVHD
may be lower in patients receiving both methotrexate
(MTX) and cyclosporine (CsA) than in those who re-
ceive either alone [21].
The failure of our studies to show a significant
effect of mHAg disparities on outcomes in unrelated
donor HSCT indicates the importance of other
genetic determinants. Although further studies may
be warranted to verify the possible biologic signifi-
cance of CD31 mismatching in unrelated donor
HSCT, the clinical utility of matching for mHAg is
limited by the lack of significant clinical correlation
with outcome and the low frequencies of many
mHAg genotypes [25,38].ACKNOWLEDGMENTS
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